15 June 2012

Proofs


Introduction to Proofs

Proofs are the heart of mathematics. Mathematics is a prerequisite for science… and understanding science is necessary for life.
If you are a math major, then you must come to terms with proofs--you must be able to read, understand and write them. What is the secret? What magic do you need to know?
There is no secret, no mystery, no magic. All that is needed is some common sense and a basic understanding of a few trusted and easy to understand techniques.

The Structure of a Proof

The basic structure of a proof is easy: it is just a series of statements, each one being either
  • An assumption or
  • A conclusion, clearly following from an assumption or previously proved result.
 Directly and inevitably to the desired conclusion- without any distractions about irrelevant details. Each step should be clear or at least clearly justified. A good proof is easy to follow. And that is all.
Biological effects of S-2-Amino-3-(3-phenylacetylimidazol-4-yl) propanoic acid:
HEP G2 cell viability test -

DMEM
0
1
5
10
25
50
[mM]








0.215
1.311
1.275
1.16
0.864
0.247
0.187
#1
0.21
1.333
1.403
1.049
0.874
0.251
0.185
#2
0.221
1.274
1.386
1.126
0.842
0.271
0.185
#3

1.264
1.332
1.042
0.797
0.253
0.189
#4








0.2153
1.2955
1.349
1.09425
0.84425
0.2555
0.1865
average
0.005508
0.032151
0.057879
0.058048
0.034219
0.01063
0.001915
Std.Dev










Additional detail:  each well contains 200ul. HEP G2 is the ATCC 'gold standard' for a hepatocellular carcinoma (liver cancer) cell line. Concentrations are expressed in millimolars [0mM], [1mM], [5mM], [10mM], [25mM], [50mM].  Column labelled 'DMEM' is only growth media - with no cells. The test wells all have 2,500cells per well. Microtitre plate was incubated for 3 days at 37*Celsius. Color developed with MTS (a tetrazolium salt)-commonly used for cell viability determinations. The plate was read on a microtitre plate reader at a wavelength of 492nm. Resulting absorbances indicate complete (100%) inhibition of HEP G2 at a concentration of [25mM]  (S)-2-Amino-3-(3-phenylacetylimadazol-4-yl)propanoic acid.

Rapid inhibition of difficult to treat cancer cell lines.
Independently confirmed, reproducible, effective and undisputed...
 

 quod erat demonstrandum

And that is all.


10 March 2012

Differentiation

How is this different?

 In ordinary medicine, the goal is to extend life (i.e. "We’ll sacrifice the quality of your existence now … for the chance of gaining time later.").

(S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid has demonstrated antineoplastic effects with all cancers tested. Independent confirmation, reproducible in-vitro dose response curves. Cell viability testing conclusively demonstrates anticancer activity of this compound. Effective against all neoplastic ATCC cell lines tested (U-87 astrocytoma, HEP G2 hepatocellular carcinoma, A 375 human malignant melanoma). This compound does not effect healthy cells (D8 LCL 'B' cells).


Since cancerous cells tend to divide at a more frequent clip than most healthy cells, they are more vulnerable to the various mechanisms in chemotherapy drugs. However, these drugs can't decipher between a healthy cell and a cancerous cell, so they kill cells indiscriminately.

Radiation destroys the immune system, especially the bone marrow that lies at the very heart of the immune system.

Due to its damage on healthy cells, chemotherapy always causes side effects, which sometimes, last a lifetime.

Cancer patients refractile to chemotherapy and radiation therapy have limited options - until now.


A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.
No anticipated 'side-effects' (e.g. 'chemo-brain', hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).
Wide therapeutic margin.
Possible primary therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.
Excellent likelihood for good stability (and thus long shelf life).
Ease of use and administration - with oral dosing possible.
Low cost of goods.
Antibiotic properties.
New 'reagent' - opens possibilities for all science.
Possible nutritional supplement usage.
  • Rapid inhibition of difficult to treat cancer cell lines.
  • Reproducible cell viability/dose response curves.
  • Mechanism consistent with activation of apoptotic pathway.
  • Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
  • Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
  • Metabolism most probably through decarboxylation.

The Science... in detail (link)



(S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid targets neoplastic (cancerous) cells. This compound does not affect 'healthy' cells - at concentrations used to kill cancerous cells. This compound kills cancer cells. Apoptosis - in neoplastic cells.
 

 



Funding and Finances - needed to finish the 'approval process' for this antineoplastic NCE:
Science advances with your help. Funding needed for CRO toxicology, IND, clinical trials.

New drugs often cost $100,000 or more a year...

 

This compound [(S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid] kills cancer cells - 









You decide!
 Stop wishing and hoping cancer away... Make it happen.


 Regards,

Dennis Wright
drwright442000@yahoo.com



Talent does what it can; Genius does what it must.                       
 Robert Bulwer-Lytton

25 January 2012

We are already there

Text from the State Of The Union - delivered 24 January 2012:

" Innovation also demands basic research.  Today, the discoveries taking place in our federally financed labs and universities could lead to new treatments that kill cancer cells but leave healthy ones untouched. "


Take a look at this - we are already there!!!

A novel alpha amino acid, antineoplastic - no toxicity to healthy tissue.

cancer-comments.html  (Link)